Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023
Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors in Patients with Melanoma
Neurol 101:e2472-e2482, Pepys,J.,et al, 2023
Economic Evaluation of Andexanet Versus Prothrombin Complex Concentrate for Reversal of Factor Xa-Associated Intracranial Hemorrhage
Stroke 52:1390-1397, Micieli, A.,et al, 2021
Encephalitis Induced by Immune Checkpoint Inhibitors
JAMA Neurol 78:864-873, Velasco, R.,et al, 2021
Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors
Neurol 97:e191-e202, Nersesjan, V.,et al, 2021
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Deprescribing in Epilepsy
JAMA Neurol 77:673-674, Terman, S.W.,et al, 2020
Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020
Stroke Incidence and Impact of Continuous-Flow Left Ventricular Assist Devices on Cerebrovascular Physiology
Stroke 50:542-548, Cornwell, W.K.,et al, 2019
Acute Toxic Leukoencephalopathy: Etiologies, Imaging Findings, and Outcomes in 101 Patients
AJNR 40:267-275, Ozutemiz, C.,et al, 2019
Clinical Characteristics and Outcomes of Methamphetamine-Associated Intracerebral Hemorrhage
Neurol 93:e1-e7, Swor, D.E.,et al, 2019
Reversible Cerebral Vasoconstriciton Syndrome
www.UptoDate.com, June, Singhal, A., 2019
Muscular Dystrophies
Lancet 394:2025-2038, Mercuri, E.,et al, 2019
Efficacy and Tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy
Neurol 91:82-90, Kanner, A.M.,et al, 2018
Efficacy and Tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy
Neurol 91:74-81, Kanner, A.M.,et al, 2018
Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer
Neurol 91:e985-e994, Touat, M.,et al, 2018
Outcome of Intracerebral Hemorrhage Associated with Different Oral Anticoagulants
Neurol 88:1693-1700,1686, Wilson, D.,et al, 2017
Pharmacotherapy for Diabetic Peripheral Neuropathy Pain and Quality of Life
Neurol 88:1958-1967, Waldfogel, J.M.,et al, 2017
Migraine
NEJM 377:553-561, Charles, A., 2017
Zolpidem for the Treatment of Neurologic Disorders
JAMA Neurol 74:1130-1139, Bomalaski, M.N.,et al, 2017
Recrudescence of Deficits After Stroke
JAMA Neurol 74:1048-1055, Topcuoglu, M.A.,et al, 2017
Infliximab for the Treatment of CNS Sarcoidosis
Neurol 89:2092-2100, Gelfand, J.M.,et al, 2017
Clinicopathologic Conference, Copper Deficiency Myelopathy
NEJM 377:1977-1984, Case 35-2017, 2017
Early Clinical and Radiological Course, Management, and Outcome of Intracerebral Hemorrhage Related to New Oral Anticoagulants
JAMA Neurol 73:169-177,155, Purrucker, J.C.,et al, 2016
Statin-Associated Autoimmune Myopathy
NEJM 374:664-669, Mammen, A.L., 2016
Anticoagulant Reversal, Blood Pressure Levels, and Anticoagulant Resumption in Patients with Anticoagulation-Related Intracerebral Hemorrhage
JAMA 313:824-836, Kuramatsu, J.B.,et al, 2015
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
Ischemic Optic Neuropathies
NEJM 372:2428-2436, Biousse, V. & Newman, N.J., 2015
Microbleed Status and 3-Month Outcome After Intravenous Thrombolysis in 717 Patients with Acute Ischemic Stroke
Stroke 46:2458-2463,2403, Turc, G.,et al, 2015
Serotonin Syndrome
BMJ 348:g1626, Buckley, N.A.,et al, 2014
Anesthetic Drugs in Status Epilepticus: Risk or Rescue?
Neurol 82:656-664, Sutter, R.,et al, 2014
Triptans for Symptomatic Treatment of Migraine Headache
BMJ 348:g2285, Pringsheim, T. & Becker, W.J., 2014
ICU-Acquired Weakness and Recovery from Critical Illness
NEJM 370:1626-1635, Kress, J.P. & Hall, J.B., 2014
Myasthenia in Pregnancy: Best Practice Guidelines from a UK Multispecialty Working Group
JNNP 85:538-543, Norwood, F.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Remote or Extraischemic Intracerebral Hemorrhage - An Uncommon Complication of Stroke Thrombolysis
Stroke 45:1657-1663, Mazya, M.V.,et al, 2014
Symptomatic Intracerebral Hemorrhage in Acute Ischemic Stroke After Thrombolysis With Intravenous Recombinant Tissue Plasminogen Activator
JAMA Neurol 81:1181-1185, Yaghi, S.,et al, 2014
Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Erythromelalgia? A Clinical Study of People Who Experience Red, Hot, Painful Feet in the Community
Int J Vasc Med ID=864961, Friberg, D.,et al, 2013
The Spectrum of Statin Myopathy
Curr Opin Rheumatol 25:747-752, Mohassel, P. & Mammen, A.L., 2013
Using Dabigatran in Patients with Stroke A Practical Guide for Clinicians
Stroke 43:271-279, Alberts, M.J.,et al, 2012
Statins and Intracerebral Hemorrhage
Arch Neurol 69:39-45,13, Hackam,D.G,et al, 2012
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Evidence-Based Guideline: Pharmacologic Treatment of Chorea in Huntington Disease
Neurol 79:597-603, Armstrong, M.J. & Miyasaki, J.M., 2012
Hyperosmolar Therapy for Raised Intracranial Pressure
NEJM 367:746-752, Ropper, A.H., 2012
Dropped Head Syndrome: Report of Three Cases During Treatment with a Mek Inhibitor
Neurol 79:1929-1932, Chen, X.,et al, 2012
Substitution Monotherapy with Levetiracetam vs Older Antiepileptic Drugs
Arch Neurol 69:1563-1571, Hakami, T.,et al, 2012
Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Arch Neurol 68:186-191, Miravalle,A.,et al, 2011
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
Neurol 76:1697-1704, Vermersch,P.,et al, 2011